Clene to File Accelerated Approval NDA for ALS Drug CNM-Au8 Following Positive FDA Meeting
Summary
Clene Inc. announced positive feedback from the FDA, indicating its data may support an accelerated approval New Drug Application (NDA) for its ALS drug candidate, CNM-Au8, which the company plans to submit in Q3 2026.
Key Events
-
FDA Greenlights Accelerated Approval Pathway
The FDA stated that Clene's proposed data may be capable of supporting an accelerated approval New Drug Application (NDA) for CNM-Au8 for the treatment of ALS.
-
NfL Acknowledged as Potential Surrogate Endpoint
The FDA noted that Neurofilament light (NfL) could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval for CNM-Au8.
-
NDA Submission Planned for Q3 2026
Clene Inc. intends to submit its New Drug Application (NDA) for CNM-Au8 to the FDA in the third quarter of 2026.
-
Phase 3 Confirmatory Study to Commence in Q1 2027
The company is conducting a Phase 3 confirmatory study for CNM-Au8, which it intends to commence in the first quarter of 2027.
Analysis
This announcement is a critical positive development for Clene Inc., especially given the company's recent disclosure of substantial doubt about its ability to continue as a going concern. The FDA's indication that Clene's data may support an accelerated approval pathway for its ALS drug candidate, CNM-Au8, and the acknowledgment of Neurofilament light (NfL) as a potential surrogate endpoint, significantly de-risks the regulatory path. An accelerated approval could bring the drug to market much faster, providing a potential revenue stream that is vital for the company's long-term viability. Investors should closely monitor the planned NDA submission in Q3 2026 and the subsequent FDA review process, as this represents a major step towards commercialization and could fundamentally alter the company's financial outlook.
At the time of this filing, CLNN was trading at $6.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.3M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.